Brokerages Set ABIVAX Société Anonyme (NASDAQ:ABVX) Price Target at $38.67

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have been given an average recommendation of “Buy” by the seven brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $38.67.

ABVX has been the subject of a number of analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th.

Institutional Trading of ABIVAX Société Anonyme

A number of institutional investors and hedge funds have recently modified their holdings of ABVX. abrdn plc lifted its stake in shares of ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after buying an additional 198,225 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares during the last quarter. Walleye Capital LLC lifted its stake in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after buying an additional 80,807 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in shares of ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after buying an additional 119,300 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new stake in shares of ABIVAX Société Anonyme in the fourth quarter worth $29,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Trading Up 6.0 %

NASDAQ ABVX opened at $8.08 on Monday. The company has a 50 day moving average price of $6.83 and a two-hundred day moving average price of $9.17. ABIVAX Société Anonyme has a 12-month low of $5.49 and a 12-month high of $17.02.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.